Table 1 In vivo solid cancer preventive effects of CDDO-Me
Effects | Mechanisms | Dose/duration | Route | Reference |
|---|---|---|---|---|
Decreased the average tumor burden of vinyl carbamate-induced andenocarcinoma in female A/J mice | Suppression of the ability of IFN-γ to induce de novo formation of NO synthase; Induction of HO-1; Suppression of phosphorylation of STAT3 as well as induction of apoptosis | 60 mg/kg, 2 weeks | Diet | [16] |
Prevented the formation of ER- negative mammary tumors in the mouse mammary tumor virus-neu transgenic model | Inhibited constitutive STAT3 phosphorylation and the degradation of IKBα | 60 mg/kg, 45 weeks | Diet | [17] |
Increased survival of the KPC mice by 3 to 4 weeks | Interacted with both STAT3 and IKK to decrease constitutive IL-6 secretion, inhibited constitutive STAT3 phosphorylation, and blocked the degradation of IKBα when challenged with TNF-α | 60 mg/kg diet or 15 mg/kg body weight. Beginning at 4 weeks of age until detect tumor | Diet | [18] |
Delayed ER–negative mammary carcinogenesis in polyoma middle T Mice | Inhibited cyclin D1 and decreased phosphorylation of EGFR and STAT3 | 50 mg/kg, 4–8 weeks | Diet | [19] |
Delayed tumor development in the BRCA1-mutated mice by an average of 5.2Â weeks | Interacted with ErbB2, decreased constitutive phosphorylation of ErbB2, inhibited proliferation, and induced G0/G1 arrest | 50Â mg/kg. Beginning at 12Â weeks of age until detect tumor | Diet | [20] |
Inhibited the progression of preneoplastic lesions in the DLP and VP lobes to adenocarcinoma in TRAMP mice | Inhibited cell proliferation, reduced the density of blood vessels and promoted apoptosis in the prostatic tissue | 10 μmol/kg. 20 weeks | Oral gavage | [21] |
Inhibited the progression of the preneoplastic lesions to adenocarcinoma in the DLP and VP lobes of TRAMP mice | Inhibited the expression of prosurvival p-Akt and NF-κB in the prostate | 7.5 mg/kg/day, 5 days/week. Early intervention initiated at five weeks of age for 20 weeks. Delayed administration started at 12 week of age for 12 weeks | Oral gavage | [22] |
Inhibited the progression of preneoplastic lesions to adenocarcinoma of the prostate in TRAMP mice | Decreased TERT and its regulatory proteins in the prostate | 15 μmol/kg/day, 5 days/week, 20 weeks | Oral gavage | [23] |